Track market-moving stories before they get noisy

Beam Therapeutics Inc. (BEAM) Discusses Updated Phase 1/2 Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Transcript

BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months Follow-Up, Data Show Long-Term Durability of In Vivo Correction of Disease-causing Mutation with Single Dose of BEAM-302 Treatment with BEAM-302 Increased Total and Functional AAT and Decreased Neutrophil Elastase Activity in Circulation BEAM-302 Led to Reduction in Circulating Mutant Z-AAT and Corresponding Decrease in Toxic Circulating Z-polymers Safety Profile of BEAM-302 Remains Consistent with LNP-based Therapies Dosing Underway in Global Pivotal Cohort Designed to Support Potential U.S. Accelerated Approval Beam to Host Investor Webcast Today, September 8, 2026, at 7:00 a.m. ET CAMBRIDGE, Mass.

 | Source: Beam Therapeutics

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Eric Foster as chief commercial officer. Mr. Foster will lead Beam’s commercial organization and strategy as the company advances multiple product candidates across its hematology and genetic disease franchises toward potential launches.

“Eric is an exceptional biopharmaceutical leader with a proven track record of building high-performing commercial organizations in specialty and rare disease markets,” said John Evans, chief executive officer of Beam Therapeutics. “His decades of commercial leadership are impressive, including spearheading the commercial success of multiple blockbuster rare disease franchises at Horizon Therapeutics during a period of significant growth prior to its acquisition by Amgen. As we prepare for the potential launch of risto-cel in 2027, Eric's experience building strong teams and culture, defining and executing clear commercial strategies, and leading through growth will be invaluable as we lay the foundation for Beam's next chapter and work to bring multiple precision genetic medicines to patients in the years ahead.”

Mr. Foster brings more than 25 years of commercial leadership experience across biotechnology and specialty pharmaceuticals and most recently served as chief commercial officer at Ardelyx. Prior to Ardelyx, Mr. Foster served as senior vice president and U.S. general manager at Amgen following the acquisition of Horizon Therapeutics in October 2023. At Horizon, he was senior vice president and general manager of the gout and ophthalmology business units, where he led operations for franchises that represented $2.75 billion in net sales revenue. Prior to his time at Horizon, from 2010 to 2021, Mr. Foster held roles of increasing responsibility in sales and marketing at GlaxoSmithKline across a variety of immunology and rare disease products, including serving as vice president of immunology marketing, senior global marketing director and field sales vice president. Mr. Foster began his career in sales and market access at Johnson & Johnson. Mr. Foster holds a Bachelor of Arts in Economics from the University of Georgia and a Master of Business Administration from Auburn University.

“I'm excited to join Beam at such an important moment in the company's evolution,” said Foster. “Beam has built one of the most innovative platforms and deepest pipelines in biotechnology, with the potential to redefine how serious genetic diseases are treated. I look forward to partnering with the talented team at Beam to build a leading commercial organization, establish the capabilities needed to support multiple potential launches and, ultimately, bring these transformative medicines to patients.”

About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing lifelong cures to patients suffering from serious diseases.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, statements related to: the timing and effective date of the appointment of Mr. Foster; the contributions Mr. Foster may make in his role with the company; the therapeutic applications and potential of our technology; the anticipated timing of potential product launches, including any potential launch of risto-cel; our plans to advance our programs; the sufficiency of our capital resources to fund operating expenses and capital expenditure requirements; and our ability to develop life-long, curative, precision genetic medicines for patients through base editing. Each forward-looking statement is subject to important risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: our ability to develop, obtain regulatory approval for, and commercialize our product candidates, which may take longer or cost more than planned; our ability to raise additional funding, which may not be available; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the uncertainty that our product candidates will receive regulatory approval necessary to initiate human clinical trials; that preclinical testing of our product candidates and preliminary or interim data from preclinical studies and clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that initiation and enrollment of, and anticipated timing to advance, our clinical trials may take longer than expected; that our product candidates or the delivery modalities we rely on to administer them may cause serious adverse events; that our product candidates may experience manufacturing or supply interruptions or failures; risks related to competitive products; our ability to build and scale commercial infrastructure, including a sales and marketing organization, to support potential product launches; and the other risks and uncertainties identified under the headings “Risk Factors Summary” and “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and in any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.

Contacts:

Investors:
Holly Manning
Beam Therapeutics
[email protected]

Media:
Josie Butler
1AB
[email protected]

Key Takeaways BEAM reported a Q2 loss of $1.18 per share and revenues of $0.5 million, missing consensus estimates. BEAM expects to file a BLA for risto-cel by year-end, with updated clinical data due by end-2026. BEAM advanced BEAM-302, dosed the first pivotal cohort patient, and targets an accelerated approval pathway. Beam Therapeutics (BEAM - Free Report) incurred a loss of $1.18 per share in the second quarter of 2026, wider than the Zacks Consensus Estimate of a loss of $1.00. The company had reported a loss of $1.00 per share in the year-ago quarter.

Revenues totaled $0.5 million, which missed the Zacks Consensus Estimate of $30 million. The company had recorded revenues of $8.5 million in the year-ago quarter. The top line primarily comprises license and collaboration revenues.

Year to date, shares of Beam Therapeutics have risen 2.3% compared with the industry’s 1.6% growth.

Image Source: Zacks Investment Research

BEAM's Q2 Results in DetailResearch and development expenses were $95.1 million in the second quarter, down 6.5% from the year-ago quarter.

General and administrative expenses increased 18.9% year over year to $31.9 million.

As of June 30, 2026, Beam Therapeutics had cash, cash equivalents and marketable securities worth $1.2 billion, roughly consistent with $1.21 billion as of March 31, 2026. The company expects its cash position, along with the anticipated $200 million to be drawn from its financing agreement with Sixth Street, to support operations into mid-2029.

BEAM's Pipeline UpdatesBeam Therapeutics is developing its leading ex-vivo genome-editing candidate, risto-cel, in the phase I/II BEACON study for the treatment of patients with sickle cell disease (SCD), an inherited blood disorder.

Patient dosing has been completed, with updated clinical data expected by the end of 2026. BEAM plans to submit a biologics license application (BLA) for risto-cel by the end of this year.

Beam Therapeutics is also expanding its genetic disease pipeline by developing BEAM-301 and BEAM-302 for the treatment of glycogen storage disease type Ia (GSDIa) and alpha-1 antitrypsin deficiency (AATD), respectively.

BEAM-301 is being evaluated in a phase I/IIdose-exploration study in patients with GSDIa. Initial data from the study are expected in 2026.

The company is developing BEAM-302 in an ongoing phase I/II dose-escalation study for the treatment of AATD. In March, BEAM announced positive updated data from the study showing that BEAM-302 produced durable increases in functional AAT levels, significant reductions in mutant Z-AAT and generation of corrected M-AAT with a favorable safety profile across single doses up to 75 mg.

Following FDA feedback, Beam Therapeutics aims to pursue an accelerated approval pathway for BEAM-302. In July, the company dosed the first patient in the global pivotal cohort of its ongoing phase I/II study, supporting an accelerated approval pathway in the United States ahead a future BLA filing. Updated clinical data will be presented in September 2026.

Dosing in the ongoing phase I healthy volunteer study, evaluating BEAM-103, an anti-CD117 monoclonal antibody for the treatment of SCD, has been completed.The treatment was well tolerated across all dose levels tested.

The company expanded its liver-targeted genetic disease franchise with BEAM-304 for the treatment of phenylketonuria (PKU). In June, the FDA cleared its investigational new drug application, enabling the start of a phase I/II study. The study will initially evaluate safety and efficacy in PKU patients with the R408W mutation in the United States.

BEAM’s Zacks Rank & Stocks to ConsiderBeam Therapeutics currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Harmony Biosciences (HRMY - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy) and Altimmune (ALT - Free Report) , which carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 90 days, earnings per share estimates for Harmony Biosciences have decreased from $3.34 to $3.33 for 2026. Over the same period, estimates for earnings per share increased from $3.79 to $3.87 for 2027. HRMY shares have risen 3.6% year to date.

Harmony Biosciences missed on earnings in each of the trailing four quarters, delivering an average negative surprise of 25.16%.

Over the past 90 days, estimates for Liquidia’s 2026 earnings per share have increased to $3.02 from $1.50. Over the same period, EPS estimates for 2027 have risen to $5.31 from $2.91. LQDA shares have gained 156.3% year to date.

Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.

Over the past 90 days, estimates for Altimmune’s loss per share have narrowed from $1.00 to 64 cents for both 2026 and 2027. ALT shares have declined 15% year to date.

Altimmune’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 15.81%.

August 04, 2026 07:00 ET  | Source: Beam Therapeutics

Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026

Dosing Complete for All Adult and Adolescent Patients in Phase 1/2 BEACON Trial of Risto-cel in Sickle Cell Disease; U.S. Biologics License Application (BLA) Submission Expected as Early as Year-End 2026

Clinical Trial Start-up Activities Underway Following U.S. FDA Clearance of Investigational New Drug (IND) Application for BEAM-304 in Phenylketonuria (PKU)

Ended Second Quarter 2026 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans into mid-2029

CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported second quarter 2026 financial results and provided updates across the company’s hematology and genetic disease franchises.

“The second quarter marked another period of rapid progress and disciplined execution on the clinical, regulatory and operational milestones we set for Beam,” said John Evans, chief executive officer of Beam Therapeutics. “Importantly, this progress enabled dosing of the first patient in the global pivotal cohort evaluating BEAM-302, the most advanced genetic medicine in development for AATD, which has the potential to fundamentally change the treatment paradigm for patients. In addition, we completed dosing for all adult and adolescent SCD patients in the BEACON trial of risto-cel and received FDA clearance of the IND for BEAM-304 in PKU, paving the way to the clinic for this next potentially high-value franchise. Looking ahead, we believe Beam is positioned to achieve several important milestones, including updated clinical data for BEAM-302 at the ERS Congress, rapid enrollment in the BEAM-302 pivotal cohort, first-in-human data for BEAM-301 in GSDIa, and the expected BLA submission for risto-cel. With the continued expansion and advancement of our base editing pipeline, we have the potential to deliver transformative therapies for many patients with serious genetic diseases.”

Second Quarter 2026 and Recent Progress and Anticipated Milestones

Liver-targeted Genetic Disease Franchise

BEAM-302: Beam’s lead genetic disease program is designed to be a best-in-class and first-in-class liver-targeting therapy for alpha-1 antitrypsin deficiency (AATD) that directly corrects the root cause of the disease and therefore has the potential to address both liver and lung manifestations of AATD.

In July, Beam dosed the first patient in the global pivotal cohort of the ongoing Phase 1/2 trial evaluating BEAM-302 in patients with AATD-associated lung disease, with or without liver disease. The cohort is designed to support a potential accelerated approval path in the United States.Detailed and updated clinical data for BEAM-302 were selected for a late-breaking oral presentation at the European Respiratory Society (ERS) Congress, taking place September 5-9, 2026, in Barcelona, Spain. BEAM-304: BEAM-304 is designed to leverage Beam’s proprietary and clinically validated base editing technology and lipid nanoparticle (LNP) delivery capabilities to directly and durably correct mutations in the phenylalanine hydroxylase (PAH) gene that cause phenylketonuria (PKU). Beam aims to advance BEAM-304 using an innovative platform approach with the goal of creating mutation-specific base editors for the majority of patients with PKU. 

In June, Beam announced that the U.S. Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for BEAM-304.Beam has initiated clinical start-up activities for the planned Phase 1/2 trial for BEAM-304. The trial will initially evaluate safety, tolerability, and reduction of blood Phe levels in PKU patients with the R408W mutation, one of the most prevalent disease-causing mutations among patients with PKU in the U.S., with a goal of establishing clinical proof of concept for base editing in PKU. The trial will subsequently evaluate base editors for additional mutations within a single clinical program.In July, updated preclinical data for BEAM-304 were presented at the Federation of American Societies for Experimental Biology (FASEB) Genome Engineering: Research and Applications Conference. The presentation is available on the Presentation and Publications page of Beam’s website beamtx.com.
BEAM-301: BEAM-301 aims to correct one of the most common disease-causing mutations, R83C, in patients with glycogen storage disease type Ia (GSDIa).

BEAM-301 is currently being evaluated in an open-label Phase 1/2 dose-exploration trial in patients with GSDIa.Beam expects to report initial clinical data in 2026. Hematology Franchise

Risto-cel: Ristoglogene autogetemcel (risto-cel, formerly known as BEAM-101) is an investigational autologous cell therapy with a potential best-in-class profile for the treatment of sickle cell disease (SCD). 

Dosing is complete in all adult and adolescent patients enrolled in the Phase 1/2 BEACON trial.Beam expects to report updated data for the BEACON trial by year-end 2026 and submit a biologics license application (BLA) for risto-cel as early as year-end 2026. Next-generation Programs in Sickle Cell Disease and Hematology:

Beam completed enrollment and dosing in the Phase 1 healthy volunteer clinical trial of BEAM-103, an anti-CD117 monoclonal antibody with the potential to enable non-genotoxic ex vivo and in vivo therapies for SCD. Treatment with BEAM-103 was well tolerated across all doses tested.Beam continues to make significant investments in developing targeted LNPs to deliver gene editing to hematopoietic stem cells (HSCs). Targeted LNPs for HSC delivery have been identified and are in lead optimization. Second Quarter 2026 Financial Results

Cash Position: Cash, cash equivalents and marketable securities were $1.2 billion as of June 30, 2026, compared to $1.2 billion as of December 31, 2025.Research & Development (R&D) Expenses: R&D expenses were $95.1 million for the second quarter of 2026, compared to $101.8 million for the second quarter of 2025.General & Administrative (G&A) Expenses: G&A expenses were $31.9 million for the second quarter of 2026, compared to $26.9 million for the second quarter of 2025.Net Income (Loss): Net loss was $122.7 million, or $1.18 per share, for the second quarter of 2026, compared to net loss of $102.1 million, or $1.00 per share, for the second quarter of 2025. Cash Runway
Beam expects that its cash, cash equivalents and marketable securities as of June 30, 2026, together with an additional $200 million expected to be drawn from the company’s facility with Sixth Street, will fund anticipated operating expenses and capital expenditure requirements into mid-2029, funding the company through the anticipated launch of risto-cel in SCD, execution of the BEAM-302 pivotal development plan in AATD, and clinical proof of concept for BEAM-304 in PKU.

About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing lifelong cures to patients suffering from serious diseases.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, statements related to: the therapeutic applications and potential of our technology, including with respect to SCD, AATD, PKU and GSDIa; our plans, and anticipated timing, to advance our programs and present data from ongoing clinical trials; the clinical trial designs and expectations for risto-cel, BEAM-103, BEAM-301, BEAM-302 and BEAM-304; our planned submission of a BLA for risto-cel; our expectations regarding the anticipated launch of risto-cel; the potential for an accelerated approval path for BEAM-302; our expected presentations at upcoming medical conferences, including at the ERS Congress; our anticipated regulatory interactions and filings; our expectations regarding the funds that will be available to draw under our credit facility; the sufficiency of our capital resources to fund operating expenses and capital expenditure requirements and the period in which such resources are expected to be available; and our ability to develop lifelong, curative, precision genetic medicines for patients through base editing. Each forward-looking statement is subject to important risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: our ability to develop, obtain regulatory approval for, and commercialize our product candidates, which may take longer or cost more than planned; our ability to raise additional funding, which may not be available; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the uncertainty that our product candidates will receive regulatory approval necessary to initiate or continue human clinical trials; that preclinical testing of our product candidates and preliminary or interim data from preclinical studies and clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that initiation and enrollment of, and anticipated timing to advance, our clinical trials may take longer than expected; that our product candidates, including the delivery modalities we rely on to administer them, may cause serious adverse events; that we may not achieve the funding milestones under our credit facility; that our product candidates may experience manufacturing or supply interruptions or failures; risks related to competitive products; and the other risks and uncertainties identified under the headings “Risk Factors Summary” and “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, and in any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.

Contacts:
Investors:
Holly Manning
Beam Therapeutics
[email protected]

Media:
Josie Butler
1AB
[email protected]

  Condensed Consolidated Balance Sheet Data (unaudited)(in thousands)       June 30,
2026 December 31,
2025Cash, cash equivalents, and marketable securities$1,152,927  $1,245,210 Total assets 1,386,355   1,481,177 Total liabilities 318,913   242,819 Total stockholders’ equity 1,067,442   1,238,358          Condensed Consolidated Statement of Operations (unaudited)(in thousands, except share and per share data)             Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025License and collaboration revenue$490  $8,466  $32,228  $15,936 Operating expenses:           Research and development 95,096   101,758   199,620   200,574 General and administrative 31,947   26,859   66,376   54,799 Total operating expenses 127,043   128,617   265,996   255,373 Loss from operations (126,553)  (120,151)  (233,768)  (239,437)Other income (expense):           Change in fair value of derivative liabilities (4,200)  1,300   (1,700)  4,500 Change in fair value of non-controlling equity investments 338   4,415   354   2,334 Change in fair value of contingent consideration liabilities (205)  (28)  309   (55)Gain on sale of equity method investment 455   —   455   — Interest and other income (expense), net 7,487   12,326   17,354   22,190 Total other income (expense) 3,875   18,013   16,772   28,969 Net loss$(122,678) $(102,138) $(216,996) $(210,468)Unrealized gain (loss) on marketable securities (1,119)  (150)  (3,300)  (669)Comprehensive loss$(123,797) $(102,288) $(220,296) $(211,137)Net loss per common share, basic and diluted$(1.18) $(1.00) $(2.09) $(2.21)Weighted-average common shares outstanding, basic and diluted 104,325,436   101,995,184   103,797,276   95,023,977                 

CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated clinical data from the Phase 1/2 trial evaluating BEAM-302 for alpha-1 antitrypsin deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026, taking place September 5–9, 2026, in Barcelona, Spain.

Posted by Defense World Staff on Jul 21st, 2026

Amova Asset Management Americas Inc. lowered its stake in Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 13.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,825,585 shares of the company’s stock after selling 583,715 shares during the quarter. Beam Therapeutics makes up 1.3% of Amova Asset Management Americas Inc.’s investment portfolio, making the stock its 24th largest holding. Amova Asset Management Americas Inc. owned about 3.72% of Beam Therapeutics worth $91,164,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of BEAM. Hollencrest Capital Management purchased a new stake in shares of Beam Therapeutics in the 1st quarter valued at approximately $43,000. Bank Julius Baer & Co. Ltd Zurich acquired a new position in Beam Therapeutics in the 4th quarter worth approximately $47,000. Larson Financial Group LLC grew its position in Beam Therapeutics by 4,370.5% during the 3rd quarter. Larson Financial Group LLC now owns 1,967 shares of the company’s stock worth $48,000 after purchasing an additional 1,923 shares in the last quarter. Van ECK Associates Corp grew its position in Beam Therapeutics by 48.7% during the 3rd quarter. Van ECK Associates Corp now owns 2,158 shares of the company’s stock worth $52,000 after purchasing an additional 707 shares in the last quarter. Finally, Kestra Advisory Services LLC acquired a new stake in Beam Therapeutics during the 4th quarter valued at $59,000. Institutional investors and hedge funds own 99.68% of the company’s stock.

Insider Buying and Selling In other news, insider Fmr Llc sold 251,488 shares of the stock in a transaction on Friday, June 26th. The shares were sold at an average price of $35.26, for a total transaction of $8,867,466.88. Following the transaction, the insider owned 854,583 shares in the company, valued at $30,132,596.58. This represents a 22.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 3.80% of the stock is owned by corporate insiders.

Beam Therapeutics Stock Down 4.4% BEAM opened at $26.33 on Tuesday. Beam Therapeutics Inc. has a fifty-two week low of $15.60 and a fifty-two week high of $38.26. The business has a 50-day moving average of $31.47 and a 200-day moving average of $29.31. The company has a debt-to-equity ratio of 0.09, a current ratio of 16.99 and a quick ratio of 16.99. The company has a market capitalization of $2.71 billion, a PE ratio of -38.72 and a beta of 2.18.

Beam Therapeutics (NASDAQ:BEAM – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.03) by $0.12. The business had revenue of $31.74 million during the quarter, compared to analysts’ expectations of $10.98 million. Beam Therapeutics had a negative return on equity of 29.00% and a negative net margin of 39.66%.The firm’s quarterly revenue was up 323.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.23) EPS. Equities research analysts forecast that Beam Therapeutics Inc. will post -4.16 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth Several analysts have recently commented on BEAM shares. Citigroup raised their target price on Beam Therapeutics from $64.00 to $68.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. Sanford C. Bernstein dropped their price target on Beam Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 13th. HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Beam Therapeutics in a research note on Tuesday, July 7th. Bank of America restated a “buy” rating and set a $47.00 price objective on shares of Beam Therapeutics in a research report on Wednesday, July 8th. Finally, Tudor Pickering set a $39.00 target price on Beam Therapeutics in a report on Wednesday, May 13th. Ten research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $46.85.

View Our Latest Research Report on BEAM

About Beam Therapeutics (Free Report)

Beam Therapeutics, Inc (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.

Featured Articles Five stocks we like better than Beam Therapeutics The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for Beam Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beam Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEDeere & Company $DE Shares Sold by AlTi Global Inc.

NEXT HEADLINE »10,396 Shares in Akamai Technologies, Inc. $AKAM Acquired by AlTi Global Inc.

Prime Medicine, Inc. secured a favorable arbitration ruling against Beam Therapeutics, allowing continued development of its PM647 gene editing program for AATD. PRME's Prime Editing platform offers precise, versatile gene correction using LNP delivery, but remains preclinical with IND/CTA filings for PM647 expected mid-2026 and initial clinical data in 2027. PRME lags competitors like Beam, Sanofi, and Arrowhead in the AATD development race, facing significant funding needs and clinical risks.

An exciting new CRISPR-based tool is making waves in the scientific literature this spring. Because the new technology destroys targeted diseased cells outright rather than editing their genetic material, it's being informally called the "DNA shredder."

For shareholders of CRISPR Therapeutics (CRSP 1.81%) and its gene-editing peers like Intellia Therapeutics (NTLA 2.30%) and Beam Therapeutics (BEAM +7.36%), the emergence of a new form of genetic medicine could have major financial implications down the road. Let's unpack what the new tech can do and what it means for CRISPR Therapeutics as well as these other stocks.

Image source: Getty Images.

This is the frontier of science, not a near-term commercial event The newly discovered tool reads a signal unique to a diseased cell and subsequently destroys that cell's DNA by cutting it into fragments faster than the cell can repair it. That continues until the cell dies once it can't reproduce its own cellular machinery; cells without the triggering sequence are spared.

In short, this is programmable cell-killing and not gene-editing. And that's a capability that could be enormously useful across a range of clinical and research applications.

The new tool is already demonstrating its potential to treat serious illnesses. A May paper published in the journal Nature from researchers at the University of Utah showed the therapy cutting the growth of lung cancer cells that are driven by mutations in one of the most common cancer-driving genes by about 50% in a lab dish. That matched the chemotherapy drug cisplatin in the same test, with no effect on healthy cells.

Today's Change

(

-1.81

%) $

-1.12

Current Price

$

60.77

A follow-up Nature paper in June from a lab at University of California, Berkeley -- one of the two labs whose 2012 work established CRISPR-Cas9 as a programmable gene-editing tool -- extended the shredding approach to target a gene that's mutated in 40% to 50% of all cancers, and one of oncology's most challenging targets to develop drugs for. All of this work remains in test tubes and animal models, with the obstacle of developing the shredder technology into a medicine that's useful to treat human patients still unsolved.

None of this new tech is in CRISPR Therapeutics' pipeline, nor in the disclosed pipelines of any of its major competitors. The closest it gets is using this editing to produce Casgevy, which CRISPR Therapeutics developed with Vertex Pharmaceuticals. Similarly, Intellia Therapeutics uses this editing as part of its candidates to treat hereditary angioedema (severe swelling) and transthyretin amyloidosis (a progressive, life-threatening disease caused by a buildup of abnormal protein deposits in organs and tissues). Beam Therapeutics uses base editors in alpha-1 antitrypsin deficiency and sickle cell disease.

Today's Change

(

-2.30

%) $

-0.41

Current Price

$

17.43

The only company working to develop a therapy using the tool is Akribion Therapeutics, a private German biotech. Its lead program targets HPV-positive head and neck cancer, but it's years from clinical trials, let alone the market.

What investors should actually take from this The most important takeaway for investors here is that the new papers significantly expand the addressable market for CRISPR-based medicine.

The ability to perform efficient cell destruction based on a genetic sequence addresses a huge problem that gene-editing alone doesn't address, specifically the possibility of competing in areas like oncology and virally driven cancers, where killing the diseased cells could constitute a breakthrough in treatment. None of the public CRISPR names is anywhere near such a breakthrough with this today, and it's unclear if they even have enough capital or expertise in oncology to pursue new programs using the shredder technology.

Today's Change

(

7.36

%) $

2.60

Current Price

$

37.92

But there is one vector where CRISPR Therapeutics and the other gene-editing stocks could become relevant players. The paper in the May issue of Nature showed promise in the same drug-delivery infrastructure that CRISPR Therapeutics, Intellia, and Beam have spent a half-decade building for their particular purposes. Having a functional delivery system for a gene-editing complex means that the next payload they invent doesn't need to include spending on making new delivery infrastructure.

So the incumbents will likely have an advantage relative to newcomers if they choose to compete.

Key Takeaways BEAM shares rose 5% after the FDA cleared the IND for BEAM-304, a gene-editing therapy for PKU.BEAM-304 targets PAH gene mutations to lower toxic Phe levels and restore PAH function.BEAM plans to initiate a phase I/II study & later expand the program to target a second mutation. Shares of Beam Therapeutics (BEAM - Free Report) rose 5% on Thursday after the FDA cleared the investigational new drug (IND) application for BEAM-304, the company’s investigational gene-editing therapy for the treatment of phenylketonuria (PKU). The clearance marks an important milestone for Beam Therapeutics as it expands its liver-targeted genetic disease franchise.

PKU is a rare inherited metabolic disorder characterized by the inability to properly break down phenylalanine (Phe), resulting in its toxic buildup in the body. If left untreated, elevated Phe levels can lead to serious neurological and cognitive complications, requiring patients to adhere to strict lifelong dietary restrictions.The disease affects approximately 20,000 people in the United States and is typically diagnosed through newborn screening. Currently, no approved curative treatments exist for PKU.

Year to date, the stock has risen 23.2% against the industry’s 1% decline.

Image Source: Zacks Investment Research

More on Beam Therapeutics’ BEAM-304BEAM-304 is a liver-targeted, lipid nanoparticle (LNP)-based gene-editing therapy designed to correct disease-causing mutations in the phenylalanine hydroxylase (PAH) gene responsible for PKU. By restoring PAH function, the therapy aims to lower toxic Phe levels, potentially allowing patients to maintain a normal diet without relying on specialized medical foods.

The candidate is being developed using an innovative approach that enables efficient evaluation of multiple mutation-specific base editors within a single clinical program through in vivo delivery. This strategy aligns with the FDA’s efforts to accelerate the development of genome-editing treatments for serious genetic diseases.

In preclinical studies, BEAM-304 demonstrated robust on-target liver editing and normalization of Phe levels in PKU mouse models at clinically relevant doses, supporting its potential as a disease-modifying therapy.

Beam plans to evaluate BEAM-304 in a phase I/II open-label clinical study designed to initially assess the safety, tolerability, blood Phe reduction and the potential for dietary liberalization of BEAM-304 in PKU patients with the R408W mutation. The therapy will be administered as an intravenous infusion. The program will then expand to evaluate a base editor targeting a second mutation, with the aim of establishing clinical proof of concept for base editing in PKU.

BEAM’s Zacks Rank & Stocks to ConsiderBeam Therapeutics currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Indivior Pharmaceuticals (INDV - Free Report) , Liquidia Corporation (LQDA - Free Report) and Immunocore (IMCR - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 30 days, earnings per share estimates for Indivior Pharmaceuticals remained unchanged at $4.05 for 2026 and $4.27 for 2027. INDV shares have risen 6.7% year to date.

Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.

Over the past 30 days, estimates for Liquidia’s earnings per share remained unchanged at $2.97 for 2026 and $4.81 for 2027. LQDA shares have surged 106.1% year to date.

Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.

Over the past 30 days, earnings per share estimates for Immunocore’s 2026 were unchanged at 6 cents for 2026 and 87 cents for 2027. IMCR shares have lost 17.6% year to date.

Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 46.66%.

Posted by Defense World Staff on Apr 7th, 2026

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) insider Christine Bellon sold 5,956 shares of Beam Therapeutics stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $24.58, for a total value of $146,398.48. Following the sale, the insider owned 109,711 shares in the company, valued at $2,696,696.38. The trade was a 5.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Christine Bellon also recently made the following trade(s):

On Thursday, January 22nd, Christine Bellon sold 1,371 shares of Beam Therapeutics stock. The stock was sold at an average price of $34.00, for a total value of $46,614.00. On Thursday, January 15th, Christine Bellon sold 18,629 shares of Beam Therapeutics stock. The stock was sold at an average price of $34.61, for a total value of $644,749.69. Beam Therapeutics Price Performance NASDAQ BEAM opened at $24.23 on Tuesday. The stock has a market capitalization of $2.47 billion, a price-to-earnings ratio of -23.99 and a beta of 2.18. Beam Therapeutics Inc. has a one year low of $13.52 and a one year high of $36.44. The business’s fifty day moving average is $26.51 and its 200-day moving average is $26.43.

Beam Therapeutics (NASDAQ:BEAM – Get Free Report) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $2.33 EPS for the quarter, topping analysts’ consensus estimates of ($1.13) by $3.46. The company had revenue of $114.11 million for the quarter, compared to analysts’ expectations of $13.22 million. Beam Therapeutics had a negative net margin of 57.24% and a negative return on equity of 30.65%. Beam Therapeutics’s revenue was up 280.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.09) EPS. Research analysts expect that Beam Therapeutics Inc. will post -4.57 EPS for the current fiscal year.

Institutional Investors Weigh In On Beam Therapeutics A number of hedge funds and other institutional investors have recently bought and sold shares of BEAM. Jones Financial Companies Lllp raised its holdings in Beam Therapeutics by 55,780.0% during the 1st quarter. Jones Financial Companies Lllp now owns 33,528 shares of the company’s stock valued at $655,000 after acquiring an additional 33,468 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Beam Therapeutics by 10.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 438,529 shares of the company’s stock valued at $8,564,000 after acquiring an additional 42,609 shares during the period. Legal & General Group Plc raised its holdings in Beam Therapeutics by 8.5% during the 2nd quarter. Legal & General Group Plc now owns 102,646 shares of the company’s stock valued at $1,746,000 after acquiring an additional 8,023 shares during the period. Rhumbline Advisers raised its holdings in Beam Therapeutics by 7.2% during the 2nd quarter. Rhumbline Advisers now owns 151,372 shares of the company’s stock valued at $2,575,000 after acquiring an additional 10,168 shares during the period. Finally, Prudential Financial Inc. bought a new stake in shares of Beam Therapeutics during the second quarter valued at about $201,000. Institutional investors own 99.68% of the company’s stock.

Wall Street Analyst Weigh In A number of equities research analysts recently commented on the stock. UBS Group assumed coverage on shares of Beam Therapeutics in a report on Wednesday, January 7th. They issued a “neutral” rating and a $28.00 price target on the stock. Citigroup boosted their price objective on Beam Therapeutics from $64.00 to $68.00 and gave the company a “buy” rating in a research note on Thursday, March 26th. Sanford C. Bernstein boosted their price objective on Beam Therapeutics from $37.00 to $41.00 and gave the company an “outperform” rating in a research note on Tuesday, January 20th. Canaccord Genuity Group started coverage on Beam Therapeutics in a research note on Friday, February 20th. They issued a “buy” rating and a $74.00 price objective on the stock. Finally, Wedbush boosted their price objective on Beam Therapeutics from $57.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $49.36.

View Our Latest Research Report on Beam Therapeutics

Beam Therapeutics Company Profile (Get Free Report)

Beam Therapeutics, Inc (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.

Featured Articles Five stocks we like better than Beam Therapeutics

Receive News & Ratings for Beam Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beam Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINENova Ltd. $NVMI Shares Bought by SG Americas Securities LLC

NEXT HEADLINE »Beam Therapeutics (NASDAQ:BEAM) Insider Amy Simon Sells 6,700 Shares

John M. Evans, CEO of Beam Therapeutics (BEAM +2.79%), executed an open-market sale of 30,078 shares on April 1, 2026, valued at approximately $739,000 according to the SEC Form 4 filing.

Transaction summaryMetricValueShares sold (direct)30,078Transaction value~$739,000Post-transaction shares (direct)1,047,205Post-transaction value (direct ownership)$25.36 millionTransaction value based on SEC Form 4 reported price ($24.58); post-transaction value based on April 1, 2026 market close ($24.22).

Key questionsHow does the size of this sale compare to Evans' recent selling activity?
The 30,078 shares sold is below the reported mean for Evans' sell-only transactions (~45,200 shares) and marks the smallest open-market sale in the last four disclosed sales, aligning with a declining direct share base.What is the impact of this sale on insider ownership and alignment?
After the transaction, Evans retains 1,047,205 direct shares and 103,000 indirect shares, with direct insider ownership now representing 1.03% of outstanding shares, sustaining a material equity interest.What was the price context for this transaction, and did it reflect a premium or discount to recent trading?
The shares were sold at around $24.58 per share, which was slightly above the April 1, 2026 closing price of $24.22 but below the closing price of $27.43 as of April 10, 2026.Does this transaction suggest a change in selling cadence or strategy?
The sale was executed under a pre-established Rule 10b5-1 trading plan, and the decrease in sale size is consistent with reduced direct share capacity from prior transactions rather than a shift in portfolio strategy.Company overviewMetricValuePrice (as of market close April 1, 2026)$24.22Market capitalization$2.79 billionRevenue (TTM)$139.74 million1-year price change60.84%* 1-year performance calculated using April 1, 2026 as the reference date.

Company snapshotBeam Therapeutics develops precision genetic medicines, including base editing therapies for sickle cell disease, beta thalassemia, T-cell acute lymphoblastic leukemia, and metabolic and rare genetic disorders.It has established multiple research collaborations and licensing agreements with pharmaceutical and biotechnology partners.The company targets patients with serious genetic diseases, with a focus on rare disease populations and partnerships with leading healthcare organizations.Beam Therapeutics is a clinical-stage biotechnology company specializing in the development of precision genetic medicines using base editing technology. The company's strategy centers on advancing a diversified pipeline of therapeutic candidates for hematologic, liver, and rare genetic disorders, leveraging collaborations with major industry players.

With a focus on innovation and strategic partnerships, Beam aims to address high unmet medical needs in the genetic medicine landscape.

What this transaction means for investorsBeam Therapeutics CEO John Evans’ April 1 sale of 30,078 company shares is not a warning sign for investors. The stock was sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

The transaction comes at a time when  Beam Therapeutics stock surged due to positive clinical data related to its ristoglogene autogetemcel (risto-cel, formerly known as BEAM-101) treatment for sickle cell disease. The company exited 2025 with revenue of $139.7 million, up from 2024’s $63.5 million.

However, its 2025 research and development costs increased year over year to $409.6 million, resulting in a loss from operations of $383.7 million. Even so, this is a reduction compared to 2024’s operating loss of $415.6 million, which is an encouraging sign.

Moreover, the company ended 2025 with $1.2 billion in cash and marketable securities. This provides a robust sum to maintain operations as it progresses development of its treatments.

Robert Izquierdo has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Beam Therapeutics. The Motley Fool has a disclosure policy.

Biotechnology stocks have seen a spike in merger and acquisition (M&A) activity. In March 2026 alone, there were 10 deals valued at approximately $31.5 billion.

A key reason for this activity is the upcoming patent cliff. This is the period when a drug loses its exclusive status and can face biosimilar competition. Analysts are forecasting that the industry faces a $300 billion patent cliff by 2030.

Two of the large-cap biopharma companies with best-selling drugs speeding toward the cliff are Merck & Co. NYSE: MRK with its blockbuster Keytruda drug and Bristol Myers Squibb NYSE: BMY with Eliquis. These are quality names that offer investors the safety of strong balance sheets and dividends.

Get CRISPR Therapeutics alerts:

There's an opportunity here for investors with an appetite for risk. That comes from the companies that could be future acquisition targets. These are companies that specialize in drugs that could change the biotech paradigm from chronic management to one-time cures.

Acquirable Assets: Which Biotechs Deserve a Higher FloorIt's not uncommon for every stock in a sector to move in tandem, but biotechnology right now requires a qualifier: the companies with the most potential are those with acquirable assets. Investors should look for three things:

The underlying science is differentiated enough that a large-cap company can’t quickly replicate it.

The company owns its intellectual property.

The drug/therapeutic has an indication that is large enough to move revenue and earnings for the acquiring company.

Many small-cap biotech names don’t meet every bar, which is only one reason this is such a tricky sector for investors. However, there are three names that investors should be watching. Each presents investors with an opportunity at a different point on the risk/maturity curve.

This isn’t predicting that these companies will be acquired. But because they check all three boxes above, as well as offer the promise of a potential one-time cure for chronic or untreatable diseases.

First-Mover Advantage in Gene EditingGene editing is a paradigm-shifting opportunity, and CRISPR Therapeutics NASDAQ: CRSP is an established pure play in the space. Unlike other names in this space, CRISPR already has a product in the market. In fact, CASGEVY delivered over $100 million in revenue in 2025. The company has also announced that patient initiations have nearly tripled year-over-year.

CRISPR Therapeutics Today

CRSP

CRISPR Therapeutics

$51.18 +0.94 (+1.88%)

As of 10:36 AM Eastern

This is a fair market value price provided by Massive. Learn more.

52-Week Range$40.00▼

$78.48Price Target$67.78

CASGEVY addresses sickle cell disease (SCD) and beta-thalassemia. Large, but relatively niche, markets. A key growth vector may come from its work in the cardiovascular space. The company’s CTX310 drug candidate is a potential one-and-done option for patients who need to quickly lower their triglyceride and LDL levels.

This is where the opportunity resides. CTX310 just delivered positive Phase 1 data. That means there’s still a runway to commercial approval, but the early results are positive.

Analysts are generally bullish on CRSP, but of the 19 analysts tracked by MarketBeat, the stock has two Sell ratings. Short interest is also around 24% as of this writing. That means investors may want to scale into a position gradually and use dips as times to be more aggressive.

High-Risk, High-Reward In Vivo EditingIf CRISPR Therapeutics represents the most commercially mature name in this space, Intellia Therapeutics NASDAQ: NTLA represents its highest stakes bet. Intellia is the pioneer of in vivo CRISPR editing. This means its therapies make edits directly inside the body rather than in a lab setting first. That distinction matters because it dramatically expands the range of diseases that gene editing can reach.

Intellia Therapeutics Today

NTLA

Intellia Therapeutics

$12.72 +0.37 (+2.98%)

As of 10:36 AM Eastern

This is a fair market value price provided by Massive. Learn more.

52-Week Range$7.95▼

$28.25Price Target$20.25

Intellia's two late-stage candidates are nexiguran ziclumeran (nex-z), developed in partnership with Regeneron for transthyretin amyloidosis (ATTR), and lonvoguran ziclumeran (lonvo-z), a wholly owned program targeting hereditary angioedema (HAE). Both are rare, underserved diseases where a one-time functional cure would represent a genuine paradigm shift from current chronic management.

The key 2026 catalysts are a Phase 3 data readout for lonvo-z in HAE, expected April 27, 2026, and progress in restarting and advancing its ATTR cardiomyopathy program after the FDA lifted the clinical hold. Either could move the stock materially in either direction. NTLA is not for the faint of heart, but for investors who believe in the in vivo thesis, this is the purest expression of it.

Precision Gene Editing’s Next FrontierWhere Intellia bets on CRISPR-Cas9, Beam Therapeutics NASDAQ: BEAM is pioneering something more precise. Its base editing technology works like a molecular pencil—rewriting a single genetic letter rather than making a double-strand cut in DNA. The technology has the potential to answer one of the persistent safety concerns that has kept some investors away from investing in gene editing stocks.

Beam Therapeutics Today

BEAM

Beam Therapeutics

$30.29 +0.88 (+3.00%)

As of 10:36 AM Eastern

This is a fair market value price provided by Massive. Learn more.

52-Week Range$15.60▼

$36.44Price Target$46.83

Beam's most advanced wholly owned program, BEAM-302, targets alpha-1 antitrypsin deficiency (AATD), a genetic disorder affecting the lungs and liver that currently has no curative treatment.

In March 2026, the company reported positive updated Phase 1/2 data and announced plans to advance into pivotal testing in the second half of the year. Its sickle cell program, risto-cel, could see a U.S. approval filing as early as late 2026.

Beam carries more early-stage risk than CRSP and faces nearer-term funding questions given its cash runway. But its differentiated platform and proximity to pivotal data make it a name worth monitoring for investors willing to take on that risk profile in exchange for the upside that a successful readout or acquisition offer could deliver.

Should You Invest $1,000 in CRISPR Therapeutics Right Now?Before you consider CRISPR Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.

While CRISPR Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Posted by Defense World Staff on Apr 29th, 2026

Concurrent Investment Advisors LLC acquired a new stake in Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 76,825 shares of the company’s stock, valued at approximately $2,130,000. Concurrent Investment Advisors LLC owned approximately 0.08% of Beam Therapeutics at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. CWM LLC increased its stake in Beam Therapeutics by 15.4% in the 4th quarter. CWM LLC now owns 2,466 shares of the company’s stock valued at $68,000 after purchasing an additional 329 shares in the last quarter. Wealth Effects LLC increased its stake in Beam Therapeutics by 4.3% in the 4th quarter. Wealth Effects LLC now owns 9,600 shares of the company’s stock valued at $266,000 after purchasing an additional 400 shares in the last quarter. Arizona State Retirement System increased its stake in Beam Therapeutics by 2.2% in the 3rd quarter. Arizona State Retirement System now owns 26,771 shares of the company’s stock valued at $650,000 after purchasing an additional 580 shares in the last quarter. Van ECK Associates Corp increased its stake in Beam Therapeutics by 48.7% in the 3rd quarter. Van ECK Associates Corp now owns 2,158 shares of the company’s stock valued at $52,000 after purchasing an additional 707 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Beam Therapeutics by 26.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,931 shares of the company’s stock valued at $137,000 after purchasing an additional 1,020 shares in the last quarter. 99.68% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Beam Therapeutics In other news, insider Christine Bellon sold 5,956 shares of Beam Therapeutics stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $24.58, for a total transaction of $146,398.48. Following the sale, the insider directly owned 109,711 shares of the company’s stock, valued at approximately $2,696,696.38. The trade was a 5.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John M. Evans sold 30,078 shares of Beam Therapeutics stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $24.58, for a total value of $739,317.24. Following the sale, the chief executive officer directly owned 1,047,205 shares in the company, valued at approximately $25,740,298.90. The trade was a 2.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 79,544 shares of company stock worth $1,899,942 over the last ninety days. 3.50% of the stock is owned by insiders.

Wall Street Analyst Weigh In BEAM has been the subject of several research analyst reports. UBS Group started coverage on Beam Therapeutics in a research note on Wednesday, January 7th. They issued a “neutral” rating and a $28.00 price objective for the company. Wedbush increased their target price on Beam Therapeutics from $57.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Sanford C. Bernstein increased their target price on Beam Therapeutics from $37.00 to $41.00 and gave the company an “outperform” rating in a report on Tuesday, January 20th. Canaccord Genuity Group started coverage on Beam Therapeutics in a report on Friday, February 20th. They set a “buy” rating and a $74.00 target price on the stock. Finally, Tudor Pickering set a $41.00 target price on Beam Therapeutics in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $49.36.

Get Our Latest Research Report on Beam Therapeutics

Beam Therapeutics Trading Up 4.8% Shares of Beam Therapeutics stock opened at $30.56 on Wednesday. Beam Therapeutics Inc. has a twelve month low of $15.35 and a twelve month high of $36.44. The stock has a market capitalization of $3.14 billion, a P/E ratio of -30.26 and a beta of 2.18. The business’s fifty day moving average price is $27.03 and its 200 day moving average price is $26.91.

Beam Therapeutics (NASDAQ:BEAM – Get Free Report) last issued its earnings results on Tuesday, February 24th. The company reported $2.33 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.13) by $3.46. Beam Therapeutics had a negative return on equity of 30.65% and a negative net margin of 57.24%.The firm had revenue of $114.11 million for the quarter, compared to analysts’ expectations of $13.22 million. During the same quarter last year, the firm earned ($1.09) earnings per share. The firm’s revenue for the quarter was up 280.3% compared to the same quarter last year. As a group, sell-side analysts predict that Beam Therapeutics Inc. will post -3.9 EPS for the current year.

About Beam Therapeutics (Free Report)

Beam Therapeutics, Inc (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.

Further Reading Five stocks we like better than Beam Therapeutics Want to see what other hedge funds are holding BEAM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report).

Receive News & Ratings for Beam Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beam Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEJabil, Inc. $JBL Stock Holdings Increased by Concurrent Investment Advisors LLC

NEXT HEADLINE »Concurrent Investment Advisors LLC Acquires 3,633 Shares of Cintas Corporation $CTAS

Beam Therapeutics Inc. (BEAM - Free Report) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to a loss of $1.24 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -4.60%. A quarter ago, it was expected that this company would post a loss of $1.13 per share when it actually produced a loss of $0.1, delivering a surprise of +91.15%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Beam Therapeutics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $31.74 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 52.44%. This compares to year-ago revenues of $7.47 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Beam Therapeutics shares have added about 16.7% since the beginning of the year versus the S&P 500's gain of 7.6%.

What's Next for Beam Therapeutics?While Beam Therapeutics has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Beam Therapeutics was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.89 on $20.82 million in revenues for the coming quarter and -$3.90 on $83.26 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Kyntra Bio (KYNB - Free Report) , is yet to report results for the quarter ended March 2026. The results are expected to be released on May 11.

This biotech drug developer is expected to post quarterly loss of $3.36 per share in its upcoming report, which represents a year-over-year change of +16%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Kyntra Bio's revenues are expected to be $1.56 million, down 43.3% from the year-ago quarter.

CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated biomarker data from the BEACON Phase 1/2 clinical trial of ristoglogene autogetemcel (risto-cel) in sickle cell disease (SCD) at the European Hematology Association 2026 Congress (EHA2026), taking place June 11-14, 2026, in Stockholm, Sweden. Risto-cel is an investigational autologous cell therapy with a potential best-in-class profile for the treatment of SCD.

Beam Therapeutics is transitioning from a scientific platform to a late-stage genetic medicine company with a clear commercial bridge. BEAM's $1.2B cash position supports a runway into mid-2029, enabling pivotal programs in sickle cell disease (Risto-cel) and AATD (BEAM-302). Risto-cel targets process efficiency and efficacy in SCD, with a potential BLA submission by year-end 2026; BEAM-302 pursues accelerated approval in AATD.

Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 PR Newswire DURHAM, N.C., May 13, 2026

Presentation Features Additional Data from the Single-dose Cohorts of the Phase 1/2 Trial, Including Detailed Safety Results, Efficacy Durability and Reduction in Human Neutrophil Elastase Activity Post-BEAM-302 Treatment May 18, 2026 16:00 ET  | Source: Beam Therapeutics

CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today presented the recently reported clinical data from the BEAM-302 Phase 1/2 trial in alpha-1 antitrypsin deficiency (AATD) at a symposium on translating scientific discovery in gene editing into clinical progress for patients with lung disease. The presentation was given by Amy Simon, M.D., chief medical officer of Beam, at the American Thoracic Society (ATS) International Conference being held in Orlando, Fla.

“At Beam, we are committed to leading innovation in the AATD community, with a goal of transforming disease outcomes for all patients suffering from this disease,” said Dr. Simon. “For BEAM-302, the data shared today build on the growing body of clinical evidence that supports the profound impact of treating AATD at the root cause of disease, the DNA mutation, with this one-time investigational therapy. We are rapidly executing toward pivotal development to deliver BEAM-302 to patients with AATD as safely and expeditiously as possible. Our long-term goal is to combine our growing understanding of AATD biology and our leading gene editing capabilities to maximize patient benefit across the entire spectrum of disease manifestations. We are also continuing to expand our cross-sector collaborations with leading AATD advocacy organizations to advance disease awareness and increase diagnosis, support the evolution of research approaches and incorporate patient perspectives across the broader scientific and care community.”

“The ongoing results from the BEAM-302 trial are truly remarkable, suggesting a single treatment dose can correct AATD at its root cause and durably restore normal AAT function, addressing both lung and liver manifestations of disease over a patient's entire lifetime,” said John Hurst, M.D., Ph.D., professor at the University College London and an investigator in the BEAM-302 trial. “This is not only a paradigm shift for the treatment of AATD, but also for medicine more widely as we enter the era of gene correction as a tool for clinicians.”

BEAM-302 is being evaluated in a Phase 1/2, open-label, dose exploration and dose expansion clinical trial to investigate its safety, tolerability, pharmacodynamics, pharmacokinetics and efficacy. Topline data from 29 patients treated with BEAM-302 as of a February 10, 2026 data cutoff date were reported in March 2026. Dr. Simon's presentation at ATS features additional data for the single-dose cohorts from the same data cutoff, including detailed safety results, efficacy durability and reduction in human neutrophil elastase activity (a direct measure of AAT function) post-BEAM-302 treatment. Dr. Simon’s presentation is available on the “Presentations and Publications” section of Beam’s website at beamtx.com.

Based on feedback from the U.S. Food and Drug Administration (FDA), Beam intends to pursue an accelerated approval pathway for BEAM-302. To support a future biologics licensing application (BLA) submission, the company anticipates enrolling approximately 50 additional patients with AATD-associated lung disease, with or without liver disease, in an expansion of the ongoing open-label Phase 1/2 trial. Beam expects to initiate this pivotal cohort in the second half of 2026. In addition, Beam expects to present detailed and updated BEAM-302 data at a medical congress in 2026.

About BEAM-302
BEAM-302 is a liver-targeting lipid-nanoparticle (LNP) formulation of base editing reagents designed to correct the PiZ mutation. Patients homozygous for this mutation (PiZZ) represent the majority of patients living with severe AATD disease. A one-time A-to-G correction of the PiZ mutation with Beam’s adenine base editor has the potential to simultaneously reduce the aggregation of mutant, misfolded AAT protein that causes toxicity to the liver (Z-AAT), generate therapeutic levels of corrected protein (M-AAT), and increase total and functional AAT in circulation, thereby addressing the underlying pathophysiology of both the liver and lung disease. In addition, the reduction in circulating PiZ has the potential to further minimize lung inflammation and dysfunction. Importantly, because BEAM-302 corrects the native AAT gene in its normal genetic location, AAT levels have been observed to increase physiologically in response to infection and inflammation in treated patients. This is a critical aspect of AAT’s normal function to regulate the body’s inflammatory response, which does not occur with currently approved protein replacement therapies. Correction of the PiZ mutation has been durable in patients treated in Beam's clinical trial.

About Alpha-1 Antitrypsin Deficiency (AATD)
AATD is an inherited genetic disorder that can cause early onset emphysema and liver disease. The most severe and common form of AATD arises when a patient has a point mutation in both copies of the SERPINA1 gene at amino acid 342 position (E342K, also known as the PiZ mutation or the “Z” allele). This point mutation causes alpha-1 antitrypsin, or AAT, to misfold, accumulating inside liver cells rather than being secreted, resulting in very low levels (10%-15%) of circulating AAT. In addition to resulting in lower levels, the PiZ AAT protein variant is also less enzymatically effective compared to wildtype AAT protein (also known as the “M” allele). As a consequence, the lung is left unprotected from neutrophil elastase, resulting in progressive, destructive changes in the lung, such as emphysema, which can result in the need for lung transplant. The mutant AAT protein also accumulates in the liver, causing liver inflammation and cirrhosis, which can ultimately cause liver failure or cancer requiring patients to undergo a liver transplant. It is estimated that more than 100,000 individuals in the U.S. have two copies of the Z allele, known as the PiZZ genotype, although only about 10% of all patients are thought to have been diagnosed. Although augmentation therapy has been approved in the U.S. for the treatment of AATD-associated lung disease, there are currently no curative treatments and significant unmet need exists for patients with AATD.

About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing lifelong cures to patients suffering from serious diseases.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, statements related to: the therapeutic applications and potential of our technology, including with respect to AATD; our plans, and anticipated timing, to advance our AATD program; the clinical trial designs and expectations for BEAM-302; our anticipated regulatory interactions and filings; and our ability to develop lifelong, curative, precision genetic medicines for patients through base editing. Each forward-looking statement is subject to important risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: our ability to develop, obtain regulatory approval for, and commercialize our product candidates, which may take longer or cost more than planned; our ability to raise additional funding, which may not be available; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the uncertainty that our product candidates will receive regulatory approval necessary to initiate or continue human clinical trials; that preclinical testing of our product candidates and preliminary or interim data from preclinical studies and clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that initiation and enrollment of, and anticipated timing to advance, our clinical trials may take longer than expected; that our product candidates, including the delivery modalities we rely on to administer them, may cause serious adverse events; that our product candidates may experience manufacturing or supply interruptions or failures; risks related to competitive products; and the other risks and uncertainties identified under the headings “Risk Factors Summary” and “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, and in any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.

Contacts:

Investors:
Holly Manning
Beam Therapeutics
[email protected]

Media:
Josie Butler
1AB
[email protected]

Beam Therapeutics Inc. (BEAM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript